EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221

Hadija Marchiori, Michele Schiavon, Chiara Roversi, Simone Zannoni, Massimiliano Fonsi, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Di Martino, Alessia Tagliavini, Chiara Dalla Man

CPT: Pharmacometrics & Systems Pharmacology · 2026-11 · 15 (11)

DOI: 10.1002/psp4.70359 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Antisense oligonucleotides are small synthetic DNA or RNA molecules that can be used to modulate gene expression, particularly to block the production of unwanted proteins. This makes them potentially powerful drugs to contrast cancer growth. Drug development is a long process that includes preclinical and clinical studies. Preclinical animal studies are designed to assess drug kinetics and safety before progressing to clinical trials, as they may predict the therapeutic dose to be used in the “first in human” (FIH) studies. This is usually achieved by applying allometric scaling methods that allow predicting the human pharmacokinetic (PK) parameters from those estimated in animals. Selecting the appropriate scaling formula reduces the risk of translational uncertainty and supports the design of FIH studies. The aim of this study is to compare the accuracy of different allometric scaling methods in predicting human PK of the antisense oligonucleotide LNA‐i‐miR‐221, a powerful inhibitor of microRNA miR‐221, which was found to be deregulated in several malignancies, favoring cancer progression. To do that, we exploited the availability of PK data of the drug in both Sprague Dawley rats and humans and we found that the best scaling method for both clearance and distribution volume is the simple allometry, with predictions laying within the 2‐fold and 4‐fold error interval, respectively. This study contributes to identifying the most accurate scaling methods among the evaluated single‐species approaches to extrapolate human pharmacokinetic for LNA‐i‐miR‐221, possibly offering a starting point for future studies involving antisense oligonucleotides.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →